Ginkgo Biloba and Desmopressin for Bedwetting in Children
Ginkgo Biloba oral tablet
+ Desmopressin Acetate 0.2 mg Tablets
+ Desmopressin like Placebo
Urogenital Diseases+9
+ Behavior
+ Mental Disorders
Treatment Study
Summary
Study start date: November 1, 2024
Actual date on which the first participant was enrolled.The study focuses on finding effective treatments for children who experience bedwetting at night, a condition known as monosymptomatic nocturnal enuresis. This is a common issue, with varying prevalence as children grow older. Traditionally, treatment has involved using alarms or medications like desmopressin, which helps reduce urine production at night. However, the study aims to explore the potential benefits of using Ginkgo Biloba, a herbal supplement known for its ability to improve sleep patterns and other health benefits, as an alternative to desmopressin. In the study, children with bedwetting issues will receive either Ginkgo Biloba or desmopressin to assess which is more effective in managing their condition. The participants will likely take the treatments orally, as these are common forms for such medications. The effectiveness of the treatments will be measured by observing changes in the frequency of bedwetting episodes. This research could offer a new treatment option that may have fewer side effects compared to traditional medications.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.398 patients to be enrolled
Total number of participants that the clinical trial aims to recruit.Treatment Study
Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.From 5 to 18 Years
Range of ages for which participants are eligible to join.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Study Plan
Find out more about all the medication administered in this study, their detailed description and what they involve.4 intervention groups are designated in this study
25% chance of being blinded to the placebo group
Treatment Groups
Group I
ExperimentalGroup II
ExperimentalGroup III
Active ComparatorGroup IV
PlaceboStudy Objectives
Primary Objectives
Study Centers
These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.This study has 1 location